LOGIN  |  REGISTER
Viking Therapeutics
Terns Pharmaceuticals

Azenta Announces Fiscal 2023 Third Quarter Earnings Conference Call and Webcast

August 03, 2023 | Last Trade: US$34.89 4.89 16.30

BURLINGTON, Mass., Aug. 3, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2023 earnings which ended on June 30, 2023 on Tuesday August 8, 2023 after the market closes.

The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday August 8, 2023, at 4:30 p.m. Eastern Time. To participate in the conference call, please dial 800-954-0585 for domestic callers and +1-212-231-2927 for international callers.

Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on August 9, 2023.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally.

Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

INVESTOR CONTACTS:
Sara Silverman
Head of Investor Relations & Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.

Sherry Dinsmore
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Chimerix

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page